{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:17:25Z","timestamp":1792300645580,"version":"4.4.0"},"reference-count":116,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is the second most common degenerative disorder. Although the disease was described more than 200 years ago, its pathogenetic mechanisms have not yet been fully described. In recent years, the discovery of the association between mutations of the GBA gene (encoding for the lysosomal enzyme glucocerebrosidase) and PD facilitated a better understating of this disorder. GBA mutations are the most common genetic risk factor of the disease. However, mutations of this gene can be found in different phenotypes, such as Gaucher\u2019s disease (GD), PD, dementia with Lewy bodies (DLB) and rapid eye movements (REM) sleep behavior disorders (RBDs). Understanding the pathogenic role of this mutation and its different manifestations is crucial for geneticists and scientists to guide their research and to select proper cohorts of patients. Moreover, knowing the implications of the GBA mutation in the context of PD and the other associated phenotypes is also important for clinicians to properly counsel their patients and to implement their care. With the present review we aim to describe the genetic, clinical, and therapeutic features related to the mutation of the GBA gene.<\/jats:p>","DOI":"10.3390\/cells8040364","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T03:15:53Z","timestamp":1555902953000},"page":"364","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":268,"title":["GBA, Gaucher Disease, and Parkinson\u2019s Disease: From Genetic to Clinic to New Therapeutic Approaches"],"prefix":"10.3390","volume":"8","author":[{"given":"Giulietta M.","family":"Riboldi","sequence":"first","affiliation":[{"name":"The Marlene and Paolo Fresco Institute for Parkinson\u2019s and Movement Disorders, NYU Langone Health, New York, NY 10017, USA"},{"name":"Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio B.","family":"Di Fonzo","sequence":"additional","affiliation":[{"name":"Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"},{"name":"Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Schiffmann","year":"2004","journal-title":"J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","article-title":"Glucocerebrosidase mutations in subjects with parkinsonism","volume":"81","author":"Lwin","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJM200502173520719","article-title":"The glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews","volume":"352","author":"Eblan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1399-0004.2006.00688.x","article-title":"Heterozygosity for a Mendelian disorder as a risk factor for complex disease","volume":"70","author":"Sidransky","year":"2006","journal-title":"Clin. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis Primers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1111\/febs.14393","article-title":"The role of glucocerebrosidase in Parkinson disease pathogenesis","volume":"285","author":"Gegg","year":"2018","journal-title":"FEBS J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/brain\/awy147","article-title":"Is Parkinson\u2019s disease a lysosomal disorder?","volume":"141","author":"Klein","year":"2018","journal-title":"Brain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.27583","article-title":"Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine","volume":"34","author":"Blandini","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","article-title":"Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies","volume":"10","author":"Chiasserini","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/mds.27136","article-title":"Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson\u2019s disease patients","volume":"32","author":"Parnetti","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: A review","volume":"75","author":"Wenstrup","year":"2002","journal-title":"Br. J. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00128072-200204070-00001","article-title":"Gaucher disease: Pediatric concerns","volume":"4","author":"Elstein","year":"2002","journal-title":"Paediatr. Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"ref_14","first-page":"158","article-title":"Delayed growth and puberty in patients with Gaucher disease type 1: Natural history and effect of splenectomy and\/or enzyme replacement therapy","volume":"2","author":"Kauli","year":"2000","journal-title":"ISR Med. Assoc. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12335","article-title":"Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature","volume":"161","author":"Arends","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_16","first-page":"1121","article-title":"Gaucher disease and related Lysosomal Storage Diseases","volume":"Volume 72","author":"Lichtman","year":"2016","journal-title":"Williams\u2019 Hematology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/17512433.2018.1549486","article-title":"Pharmacological treatment of pediatric Gaucher disease","volume":"11","author":"Gupta","year":"2018","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_18","unstructured":"Beaudet, A.L., Scriver, C.R., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W., and Vogelstein, B. (2001). Gaucher disease. The Metabolic and Molecular Basis of Inherited Disease, McGraw-Hill International Book Co.. [8th ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_20","unstructured":"Ardinger, H.H., Adam, M.P., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (2000). Gaucher Disease. GeneReviews\u00ae [Internet], University of Washington. (updated 2018 June 21)."},{"key":"ref_21","first-page":"1182","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00441578","article-title":"Gaucher disease\u2014Norrbottnian type. I. General clinical description","volume":"133","author":"Dreborg","year":"1980","journal-title":"Eur. J. Pediatrics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","article-title":"Insights into the structural biology of Gaucher disease","volume":"298","author":"Smith","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0950-3536(97)80032-7","article-title":"Gaucher\u2019s disease: Molecular, genetic and enzymological aspects","volume":"10","author":"Grabowski","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in Gaucher disease implicate the role of modifiers","volume":"42","author":"Hruska","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/clc.20348","article-title":"Gaucher disease with communicating hydrocephalus and cardiac involvement","volume":"33","author":"Cindik","year":"2010","journal-title":"Clin. Cardiol"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/humu.20217","article-title":"Gaucher mutation N188S is associated with myoclonic epilepsy","volume":"26","author":"Kowarz","year":"2005","journal-title":"Hum. Mutat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1203\/01.PDR.0000049515.79882.94","article-title":"Myoclonic epilepsy in Gaucher disease: Genotype-phenotype insights from a rare patient subgroup","volume":"53","author":"Park","year":"2003","journal-title":"Pediatr. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mds.25248","article-title":"The glucocerobrosidase E326K variant predisposes to Parkinson\u2019s disease, but does not cause Gaucher\u2019s disease","volume":"28","author":"Duran","year":"2013","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1034\/j.1399-0004.2002.610106.x","article-title":"The E326K mutation and Gaucher disease: Mutation or polymorphism?","volume":"61","author":"Park","year":"2002","journal-title":"Clin. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2011.07.002","article-title":"The enigma of the E326K mutation in acid beta-glucocerebrosidase","volume":"104","author":"Horowitz","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bcmd.2005.04.007","article-title":"Perinatal lethal phenotype with generalized ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]\/P182L genotype: Effect of the E326K change in neonatal and classic forms of the disease","volume":"35","author":"Chabas","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymgme.2011.12.002","article-title":"Is E326K glucocerebrosidase a polymorphic or pathological variant?","volume":"105","author":"Liou","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson\u2019s syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<216::AID-AJH12>3.0.CO;2-B","article-title":"Parkinson\u2019s syndrome preceding clinical manifestation of Gaucher\u2019s disease","volume":"61","author":"Machaczka","year":"1999","journal-title":"Am. J. Hematol."},{"key":"ref_38","first-page":"231","article-title":"Co-morbidity in Gaucher\u2019s disease results of a nationwide enquiry in Spain","volume":"5","author":"Bernal","year":"2000","journal-title":"Eur. J. Med. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1163\/15685590260461084","article-title":"Gaucher disease type I complicated with Parkinson\u2019s syndrome","volume":"32","author":"Varkonyi","year":"2002","journal-title":"Haematologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","article-title":"Gaucher disease with parkinsonian manifestations: Does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?","volume":"79","author":"Tayebi","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.WNL.0000072482.70963.D7","article-title":"Gaucher\u2019s disease with Parkinson\u2019s disease: Clinical and pathological aspects","volume":"61","author":"Bembi","year":"2003","journal-title":"Neurology"},{"key":"ref_42","first-page":"3136415","article-title":"A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson\u2019s Disease","volume":"2018","author":"Zhang","year":"2018","journal-title":"Parkinsons Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Velez-Pardo, C., Lorenzo-Betancor, O., Jimenez-Del-Rio, M., Moreno, S., Lopera, F., Cornejo-Olivas, M., Torres, L., Inca-Martinez, M., Mazzetti, P., and Cosentino, C. (2019). The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism Relat. Disord.","DOI":"10.1016\/j.parkreldis.2019.01.030"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease","volume":"20","author":"Lesage","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","article-title":"Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset","volume":"70","author":"Giladi","year":"2008","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson\u2019s disease: The mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s","volume":"80","author":"Liu","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.12.014","article-title":"A \u201cdose\u201d effect of mutations in the GBA gene on Parkinson\u2019s disease phenotype","volume":"36","author":"Thaler","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","article-title":"Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers","volume":"78","author":"Anheim","year":"2012","journal-title":"Neurology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","article-title":"The risk of Parkinson\u2019s disease in type 1 Gaucher disease","volume":"33","author":"Bultron","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jnnp-2012-302402","article-title":"A clinical and family history study of Parkinson\u2019s disease in heterozygous glucocerebrosidase mutation carriers","volume":"83","author":"McNeill","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/mds.24945","article-title":"Hyposmia and cognitive impairment in Gaucher disease patients and carriers","volume":"27","author":"McNeill","year":"2012","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/mds.26562","article-title":"Lysosomal Dysfunction and alpha-Synuclein Aggregation in Parkinson\u2019s Disease: Diagnostic Links","volume":"31","author":"Moors","year":"2016","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1021\/bi401191v","article-title":"Saposin C protects glucocerebrosidase against alpha-synuclein inhibition","volume":"52","author":"Yap","year":"2013","journal-title":"Biochemistry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"187.e1","DOI":"10.1016\/j.neurobiolaging.2018.06.034","article-title":"Sequencing of the GBA coactivator, Saposin C, in Parkinson disease","volume":"72","author":"Leveille","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"42105","DOI":"10.1074\/jbc.M110.172098","article-title":"Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S","volume":"285","author":"Offman","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1074\/jbc.M110.150433","article-title":"X-ray and biochemical analysis of N370S mutant human acid beta-glucosidase","volume":"286","author":"Wei","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0888-7543(89)90319-4","article-title":"The human glucocerebrosidase gene and pseudogene: Structure and evolution","volume":"4","author":"Horowitz","year":"1989","journal-title":"Genomics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0378-1119(93)90497-Q","article-title":"A novel transcript from a pseudogene for human glucocerebrosidase in non-Gaucher disease cells","volume":"136","author":"Imai","year":"1993","journal-title":"Gene"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Leija-Salazar, M., Sedlazeck, F.J., Toffoli, M., Mullin, S., Mokretar, K., Athanasopoulou, M., Donald, A., Sharma, R., Hughes, D., and Schapira, A.H.V. (2019). Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION. Mol. Genet. Genom. Med., e564.","DOI":"10.1101\/288068"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs. mild GBA mutations on Parkinson disease","volume":"84","author":"Amshalom","year":"2015","journal-title":"Neurology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","article-title":"Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes","volume":"71","author":"Alcalay","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Jesus, S., Huertas, I., Bernal-Bernal, I., Bonilla-Toribio, M., Caceres-Redondo, M.T., Vargas-Gonzalez, L., Gomez-Llamas, M., Carrillo, F., Calderon, E., and Carballo, M. (2016). GBA Variants Influence Motor and Non-Motor Features of Parkinson\u2019s Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167749"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/jnnp-2017-317348","article-title":"Features of GBA-associated Parkinson\u2019s disease at presentation in the UK Tracking Parkinson\u2019s study","volume":"89","author":"Malek","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1212\/NXG.0000000000000057","article-title":"Clinical course and prognosis in patients with Gaucher disease and parkinsonism","volume":"2","author":"Lopez","year":"2016","journal-title":"Neurol Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/archneur.64.7.1056","article-title":"Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients","volume":"64","author":"Tan","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/mds.20766","article-title":"Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela","volume":"21","author":"Eblan","year":"2006","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/jnnp.2006.105940","article-title":"Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese","volume":"78","author":"Wu","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Li, Y., Sekine, T., Funayama, M., Li, L., Yoshino, H., Nishioka, K., Tomiyama, H., and Hattori, N. (2014). Clinicogenetic study of GBA mutations in patients with familial Parkinson\u2019s disease. Neurobiol. Aging, 35.","DOI":"10.1016\/j.neurobiolaging.2013.09.019"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1212\/WNL.0b013e318225ab77","article-title":"GBA-associated PD presents with nonmotor characteristics","volume":"77","author":"Brockmann","year":"2011","journal-title":"Neurology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson\u2019s disease: Reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3233\/JPD-171172","article-title":"GBA-Associated Parkinson\u2019s Disease: Progression in a Deep Brain Stimulation Cohort","volume":"7","author":"Lythe","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/mds.26593","article-title":"GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies","volume":"31","author":"Santos","year":"2016","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1474-4422(17)30400-3","article-title":"Investigating the genetic architecture of dementia with Lewy bodies: A two-stage genome-wide association study","volume":"17","author":"Guerreiro","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.parkreldis.2014.09.003","article-title":"Glucocerebrosidase mutations in primary parkinsonism","volume":"20","author":"Asselta","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaneurol.2016.1593","article-title":"High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews","volume":"73","author":"Shiner","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.26359","article-title":"GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson\u2019s disease","volume":"31","author":"Mata","year":"2016","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Clark, L.N., Chan, R., Cheng, R., Liu, X., Park, N., Parmalee, N., Kisselev, S., Cortes, E., Torres, P.A., and Pastores, G.M. (2015). Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125204"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"208","DOI":"10.14336\/AD.2017.0505","article-title":"Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood","volume":"9","author":"Campdelacreu","year":"2018","journal-title":"Aging Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archneurol.2009.54","article-title":"Association of glucocerebrosidase mutations with dementia with lewy bodies","volume":"66","author":"Clark","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","article-title":"Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder","volume":"14","author":"Boeve","year":"2013","journal-title":"Sleep Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies","volume":"43","author":"Galbiati","year":"2019","journal-title":"Sleep Med. Rev."},{"key":"ref_90","first-page":"129","article-title":"REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders","volume":"152","author":"Marelli","year":"2014","journal-title":"Arch. Ital. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Barber, T.R., Lawton, M., Rolinski, M., Evetts, S., Baig, F., Ruffmann, C., Gornall, A., Klein, J.C., Lo, C., and Dennis, G. (2017). Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. Sleep, 40.","DOI":"10.1093\/sleep\/zsx071"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","article-title":"Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort","volume":"72","author":"Beavan","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.parkreldis.2018.02.034","article-title":"Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder","volume":"50","author":"Iranzo","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.0000000000002304","article-title":"Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder","volume":"86","author":"Iranzo","year":"2016","journal-title":"Neurology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","article-title":"Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells","volume":"82","author":"Ambrosi","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"31380","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Beavan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice","volume":"80","author":"Daly","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Migdalska-Richards, A., Ko, W.K.D., Li, Q., Bezard, E., and Schapira, A.H.V. (2017). Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse, 71.","DOI":"10.1002\/syn.21967"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuint.2015.12.004","article-title":"Advances in GBA-associated Parkinson\u2019s disease--Pathology, presentation and therapies","volume":"93","author":"Barkhuizen","year":"2016","journal-title":"Neurochem. Int."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER Stress and Autophagic Perturbations Lead to Elevated Extracellular alpha-Synuclein in GBA-N370S Parkinson\u2019s iPSC-Derived Dopamine Neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1038\/ncomms5755","article-title":"Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein","volume":"5","author":"Bae","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1073\/pnas.1321341111","article-title":"Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones","volume":"111","author":"Yang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1073\/pnas.1221046110","article-title":"Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-017-0154-3","article-title":"Therapeutic potential of autophagy-enhancing agents in Parkinson\u2019s disease","volume":"12","author":"Moors","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","article-title":"Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons","volume":"82","author":"Rocha","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_109","first-page":"166","article-title":"Gene Therapy for Neurodegenerative Diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature20414","article-title":"Defects in trafficking bridge Parkinson\u2019s disease pathology and genetics","volume":"539","author":"Abeliovich","year":"2016","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D.A., Noyce, A.J., and Xue, A. (2018). Parkinson\u2019s disease genetics: Identifying novel risk loci, providing causal insights and improving estimates of heritable risk. BioRxiv.","DOI":"10.1101\/388165"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Ysselstein, D., Shulman, J.M., and Krainc, D. (2019). Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. Mov. Disord. Off. J. Mov. Disord. Soc.","DOI":"10.1002\/mds.27631"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer\u2019s disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1474-4422(18)30232-1","article-title":"The role of TREM2 in Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"17","author":"Carmona","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/4\/364\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:46:43Z","timestamp":1760186803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/4\/364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":116,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["cells8040364"],"URL":"https:\/\/doi.org\/10.3390\/cells8040364","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,19]]}}}